| Literature DB >> 19409407 |
Anna Kakehashi1, Masayo Inoue, Min Wei, Shoji Fukushima, Hideki Wanibuchi.
Abstract
Screening of the proteome of microdissected glutathione S-transferase placental form (GST-P) positive foci and normal-appearing liver on anionic (Q10), and cationic (CM10) surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) ProteinChip arrays demonstrated significant overexpression of cytokeratin 8 (CK8; m/z 54,020), cytokeratin 18 (CK18; m/z 47,760), microsomal cytochrome 5A (m/z 15,224) and histone type 2 H2aa3 (m/z 15,964) in the livers of rats initiated with diethylnitrosamine (DEN) followed by 10 weeks on phenobarbital (PB) at a dose of 500 ppm. Furthermore, formation of CK8 and CK18 complexes due to CK8 phosphorylation at Ser73 and Ser431 was found to be strongly associated with promotion of hepatocarcinogenesis by PB and the development of hepatocellular carcinomas. The data were confirmed by immunohistochemistry and real-time Q-PCR and profound overexpression of CK8 and CK18 (CK8/18) proteins and mRNAs were detected in several large size GST-P positive foci and liver tumors. A strong correlation between CK8/18 positive foci development and multiplicity of hepatocellular carcinomas was further observed. Moreover, elevation of CK8/18 was strongly associated with induction of cell proliferation in GST-P positive foci and tumors. In conclusion, our data imply that CK8/18 overexpression, those two cytokeratins complex formation associated with histone type 2 H2aa3 up-regulation and intermediate filament reorganization may drive neoplastic transformation of GST-P positive foci during rat hepatocarcinogenesis leading to the formation of hepatocellular carcinomas.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19409407 PMCID: PMC7126293 DOI: 10.1016/j.taap.2009.04.018
Source DB: PubMed Journal: Toxicol Appl Pharmacol ISSN: 0041-008X Impact factor: 4.219
Peaks with altered expression detected by SELDI ProteinChip Array in GST-P positive foci.
| Peaks (m/z) | GST-P+ foci/DEN | Normal/DEN | GST-P+ foci/DEN → PB | Normal/DEN → PB | ||
|---|---|---|---|---|---|---|
| 8214 | 36.0 ± 5.66 | 13.5 ± 6.12 | 0.06 | 21.67 ± 8.51 | 10.3 ± 6.65 | 0.21 |
| 11,357 | 48.5 ± 4.95 | 21.0 ± 11.31 | 0.09 | 64.07 ± 43.86 | 24.0 ± 22.63 | 0.17 |
| 13,780 | 23.33 ± 17.10 | 12.67 ± 6.08 | 0.34 | 32.50 ± 14.25 | 13.33 ± 7.05 | 0.1 |
| 15,190 (CYB5A) | 15.5 ± 0.71 | 11.06 ± 5.66 | 0.34 | 57.57 ± 16.49 | 19.57 ± 11.42 | 0.018 |
| 47,761 (CK18) | 42.55 ± 4.74 | 38.55 ± 3.16 | 0.43 | 181.27 ± 12.05 | 38.67 ± 5.51 | 0.00005 |
| 54,020 (CK8) | 33.35 ± 3.32 | 22.40 ± 3.92 | 0.06 | 136.27 ± 35.25 | 28.30 ± 11.05 | 0.0072 |
| 6904 | 23. 1 ± 4.24 | 22.55 ± 3.61 | 0.90 | 107.65 ± 59.47 | 21.61 ± 9.33 | 0.18 |
| 8126 | 44.3 ± 16.97 | 90.1 ± 37.19 | 0.12 | 82.87 ± 30.67 | 24.47 ± 9.03 | 0.03 |
| 9231 | 15.0 ± 8.19 | 16.8 ± 11.52 | 0.82 | 97.87 ± 55.08 | 16.43 ± 8.36 | 0.03 |
| 11,243 | 79.93 ± 17.58 | 58.87 ± 10.10 | 0.15 | 130.97 ± 18.56 | 52.57 ± 25.74 | 0.01 |
| 13,771 | 85.33 ± 33.87 | 50.73 ± 27.88 | 0.24 | 138.07 ± 28.49 | 44.6 ± 10.61 | 0.01 |
| 13,964 (HistH2aa3) | 23.33 ± 17.10 | 12.67 ± 2.08 | 0.34 | 61.50 ± 10.65 | 13.33 ± 1.45 | 0.021 |
Fig. 1Representative findings from Q10 and CM10 ProteinChip Array showing overexpression of 8214, 11,357, 13,779, 15,224, 46,760 and 54,020 m/z peaks (Q10) and 9231, 11,243, 13,771 and 13,964 m/z peaks (CM10) in GST-P+ foci of rats treated with DEN followed by 500 ppm PB (A–D). Single marker analysis demonstrates significant up-regulation of 46,760 and 54,020 Da proteins in GST-P+ foci (E, F).
Fig. 2Double immunohistochemistry for GST-P (red) and CK8/18 (brown), and immunohistochemical assessment of PCNA in the livers of F344 rats treated with PB after DEN initiation. CK8/18 and GST-P double staining in rat liver preneoplastic lesions (A–C). Note strong homogenous overexpression of CK8/18 in GST-P+ foci (A and B) and several highly CK8/18+ cells with a low N/C ratio (C, arrow). CK8/18 and GST-P double staining in HAs, HCCs and mixed hepatocellular and chollangiocarcinomas, respectively (D–F), with immunohistochemical assessment of PCNA (G, H, F) and HE staining (J, K, L) in the same tumors.
Quantitative data for GST-P positive foci, CK8/18+ foci and liver tumors in rats undergoing initiation with DEN, with or without subsequent PB treatment.
| No. of rats | DENa | No. of rats | DEN → PB | |
|---|---|---|---|---|
| Number (no./cm2) | 10 | 128.04 ± 16.51 | 10 | 161.91 ± 36.59b |
| Area (mm2/cm2) | 1.41 ± 0.54 | 3.08 ± 0.92d | ||
| Number (No./cm2) | 10 | 1.82 ± 0.42 | 10 | 4.17 ± 1.41b |
| Area (mm2/cm2) | 0.26 ± 0.07 | 0.70 ± 0.15c | ||
| Incidence (%) | ||||
| Adenoma | 20 | 20(100) | 20 | 20(100) |
| HCC | 19(95) | 20(100) | ||
| Multiplicity (No./rat) | ||||
| Adenoma | 3.65 ± 1.90 | 4.10 ± 2.86 | ||
| HCC | 3.00 ± 1.95 | 9.60 ± 3.15d | ||
| Total | 6.65 ± 2.64 | 13.7 ± 3.53d | ||
aData are mean ± SD.
b–dSignificantly different from the DEN initiation control group.
bP < 0.01; cP < 0.001; dP < 0.0001.
Fig. 3Double immunohistochemistry for phospho-CK8 p73 (A–C) or p431 (D–F) (brown) and GST-P (red) in GST-P+ foci, HAs and HCCs; histone H2A (brown) and GST-P (red) (G–I) and immunohistochemical assessment of CK8/18 (red) and PCNA (black) (J and K) in the livers of F344 rats treated with PB after DEN initiation. Elevation of PCNA positive cells number was observed in CK8/18+ area within totally or partially stained GST-P+ foci (L). Note high expression of CK8/18 in mitotic cells in GST-P positive focus (J, arrow).
mRNA expression of CK8 and CK18 in GST-P positive foci and normal-appearing liver tissue of rats.
| Gene | DEN | DEN → PB | ||
|---|---|---|---|---|
| GST-P+ foci | Normal | GST-P+ foci | Normal | |
| CK8 | 121.86 ± 65.28 | 83.45 ± 20.22 | 1924.96 ± 1589.73 | 447.95 ± 84.85 |
| CK18 | 15.26 ± 3.01 | 15.34 ± 1.61 | 18.08 ± 8.93 | 15.03 ± 4.34 |
GST-P+ foci, GST-P positive foci; Normal, normal-appearing liver area.